Immunic (NASDAQ:IMUX) Coverage Initiated at William Blair

Equities researchers at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating on the stock.

IMUX has been the subject of a number of other research reports. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. Finally, D. Boral Capital reiterated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.67.

Immunic Stock Up 1.7 %

Shares of NASDAQ IMUX opened at $1.17 on Tuesday. The firm’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.22. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The company has a market cap of $105.39 million, a PE ratio of -0.95 and a beta of 1.89.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Jane Street Group LLC increased its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic during the 4th quarter valued at approximately $81,000. State Street Corp grew its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter worth approximately $50,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.